Aug 2026· 2026 International Conference on Modern Sustainable Systems (CMSS)· pp. 1397-1403· 0 citations· 19 references
Abstract
While the field of genomic sequencing and DNA-based precision medicine has made tremendous strides, DNA clinical trials are still plagued with numerous problems, such as low recruitment for trials, disparate genomic data integration, difficult biomarker identification, long trial times, and inconsistent treatment decisions. Restrictions in this limit trial efficiency, cost of operation and limit the progress of sustainable precision medicine. To tackle these challenges, the authors in this paper suggest a framework for optimizing DNA clinical trial and pediatric precision medicine with quantum intelligence, based on Grover's Algorithm. The proposed framework combines all the genomic sequencing information, clinical records, biomarker profiles and therapeutic knowledge in a single quantum-assisted intelligence framework. Grover's Algorithm can be used to optimize patient recruitment and biomarker discovery in highdimensional genomic search spaces; adaptive machine learning models can be used to conduct early genetic risk assessment and for personalized therapeutic recommendations. Moreover, a sustainability conscious optimisation process not only reduces the complexity of computations, but also the use of resources and the time required for clinical trials, and keeps the predictive reliability high. The proposed framework is evaluated experimentally, which shows the accuracy of participant matching is 99.12%, the precision is 98.84%, the recall is 98.67%, the F1-score is 98.75%, and the time saved in trial optimization is 36.8% compared to the other optimization and artificial intelligence frameworks. These findings demonstrate the efficacy, scalability, and sustainability of the framework, offering valuable genomic decision support, optimizing clinical trial workflow, and paving the way for precision medicine in pediatrics.
A review of the evolution of DNA circuits in disease diagnosis, with a focus on how they are becoming increasingly accurate, efficient, and intelligent.
Su-Jing Li, Sisi Wang, Yan-Bin Li et al.· Small· 0 citations
A structured view of current advances, persistent gaps, and future directions in AI-enabled pharmaceutical innovation is offered, showing growing convergence between AI and precision therapeutics, but real-world application demands robust validation, collaboration, explainable AI, and global standards.
M. Fareed, S. Shityakov· Quantum Machine Intelligence· 0 citations
A probabilistic gradient boosting model on variant pathogenicity prediction that applies biological characteristics at both level of DNA and protein levels while also scaling the level of uncertainty in clinical decision making is presented.
Karthik V, S. Prejesh, Sumedh Deepak Kudale et al.· Frontiers in Digital Health· 0 citations
This review evaluates the current state of AI applications in medicine, focusing on clinical knowledge encoding, molecular drug discovery, and administrative workflow optimization, while critically addressing the technical, ethical, and systemic challenges of their institutional implementation.
Aleksandra Stańczyk, Kinga Haduch, Zuzanna Michalska et al.· International Journal of Inn...· 0 citations
A paradigm shift toward autonomous scientific agents capable of causal reasoning and end-to-end experimental guidance is highlighted, and persistent challenges are discussed, including data bias, limited interpretability, and in silico-to-wet lab translation.